Building & Managing a High Performing Team is intended to help leaders at all levels in the biotech and biopharma industries improve how well they participate...
It’s been one year since the passage of the IRA. The Centers for Medicare & Medicaid Services has moved forward implementing the law’s various provisions, including the new Medicare negotiation program and the redesign of the Medicare Part D benefit. Learn the latest developments from our panel of experts, including how the IRA is impacting biopharmaceutical companies today. Panelists will delve into other important issues beyond the IRA, including new developments in Medicaid, 340B, and the emergence of Prescription Drug Affordability Boards in a number of states.
John Murphy, Chief Policy Officer, BIO
Crystal Kuntz, SVP, Health Policy & Reimbursement, BIO
Erin Hertzog, Partner, Foley Hoag LLP
Jim Meyers, Senior Advisor, BCG